Obstetric and Gynecologic Imaging

What Imaging Is Best for Clinically Suspected Endometrial Cancer Recurrence?

·
What Imaging Is Best for Clinically Suspected Endometrial Cancer Recurrence?

A 68-year-old woman, two years post-hysterectomy and adjuvant chemoradiation for Stage II endometrioid adenocarcinoma, presents to her gynecologic oncologist with new, persistent pelvic pain and a rising CA-125 level. On physical exam, there is subtle nodularity at the vaginal cuff. The clinical suspicion for recurrent disease is high, but the location and extent are unknown. The immediate question is which imaging study will most accurately confirm recurrence, guide a potential biopsy, and inform the next steps in management, whether it be salvage therapy or systemic treatment. This article provides a detailed workflow for this specific scenario, focusing on why the American College of Radiology (ACR) recommends specific imaging modalities. For this presentation, `MRI abdomen without and with IV contrast` is rated Usually Appropriate, offering superior soft-tissue resolution to characterize potential pelvic disease.

Who Fits This Clinical Scenario for Suspected Endometrial Cancer Recurrence?

This guidance applies specifically to patients with a confirmed history of treated endometrial cancer who now present with new signs, symptoms, or biomarker elevations suggestive of recurrence. This includes clinical findings such as:

  • New-onset vaginal bleeding or discharge
  • Pelvic, abdominal, or back pain
  • A palpable mass on physical or pelvic examination
  • Unexplained weight loss or constitutional symptoms
  • Rising serum tumor markers (e.g., CA-125), if they were initially elevated and monitored

It is critical to distinguish this scenario from others that require different imaging strategies. This workflow does not apply to:

  • Initial staging of a new endometrial cancer diagnosis. The workup for a newly diagnosed, untreated tumor involves assessing local tumor extension and distant metastasis, which follows a separate ACR pathway.
  • Routine surveillance of an asymptomatic patient. Imaging for asymptomatic follow-up is guided by the patient’s initial risk stratification (low-, intermediate-, or high-risk disease) and is typically less intensive than a workup for suspected recurrence.
  • Evaluation of a patient with a pelvic mass but no prior history of endometrial cancer. In such cases, the differential diagnosis is broader, and the imaging approach may differ.

This article is exclusively for the post-treatment patient where the clinical question is specifically “Is the cancer back, and if so, where?”

What Diagnoses Are You Working Up in Suspected Endometrial Cancer Recurrence?

When ordering imaging for suspected recurrence, the goal is to confirm the presence of disease, define its extent, and differentiate it from benign post-treatment changes. The primary diagnostic considerations include:

Local Recurrence
This is often the primary concern. Recurrent tumor can manifest in the pelvic soft tissues, most commonly at the vaginal cuff, but also along the pelvic sidewalls or involving adjacent organs like the bladder or rectum. Distinguishing small nodules of recurrent tumor from post-surgical or post-radiation fibrosis is a central diagnostic challenge that imaging must address.

Nodal Metastases
Recurrence can appear as metastatic disease in the pelvic, inguinal, or para-aortic lymph nodes. Identifying nodal disease is critical as it significantly alters treatment planning, often shifting the focus from local salvage therapy (like targeted radiation) to more extensive radiation fields or systemic therapy.

Distant Metastases
Endometrial cancer can recur in distant sites. Peritoneal carcinomatosis (seeding of the abdominal lining) is a common pattern. Other sites include the liver, lungs, and, less frequently, bone. The imaging study must be capable of evaluating these potential locations to provide a complete picture of the disease burden.

Benign Post-Treatment Changes
This is the most important mimicker of recurrence. Radiation therapy can cause fibrosis, inflammation, and scarring that may appear as soft-tissue thickening or enhancement on imaging. Similarly, post-surgical changes like granulation tissue at the vaginal cuff or benign fluid collections (seromas, lymphoceles) can create diagnostic uncertainty. A high-resolution study is needed to differentiate these benign findings from active malignancy.

Why Is MRI of the Abdomen and Pelvis Recommended for Suspected Recurrence?

For evaluating a patient with clinically suspected recurrence of endometrial cancer, the ACR designates both `MRI abdomen without and with IV contrast` and `MRI pelvis without and with IV contrast` as Usually Appropriate. These studies provide exceptional soft-tissue contrast, which is paramount for resolving the complex anatomy of the treated pelvis.

The primary strength of MRI is its ability to differentiate recurrent tumor from post-treatment fibrosis. On T2-weighted images, recurrent tumors typically appear as intermediate-signal-intensity soft-tissue masses, whereas mature fibrosis usually demonstrates low T2 signal. Furthermore, diffusion-weighted imaging (DWI) is highly sensitive for detecting cellular tumors, which show restricted diffusion (appearing bright on DWI and dark on corresponding ADC maps), a feature not typically seen in benign scar tissue. The addition of IV contrast helps delineate the vascularity and extent of any suspicious lesions.

While MRI is the top choice for pelvic evaluation, other modalities are also highly rated for their ability to assess the entire body for metastatic disease:

  • FDG-PET/CT skull base to mid-thigh is also rated Usually Appropriate. Its strength lies in its ability to detect metabolically active disease anywhere in the body, making it excellent for identifying nodal and distant metastases that might be missed on a focused pelvic MRI. It is often the preferred study when distant recurrence is highly suspected or when MRI findings are equivocal.
  • CT chest abdomen pelvis with IV contrast is another Usually Appropriate option. It provides a rapid, comprehensive evaluation of the chest, abdomen, and pelvis, and is particularly effective for detecting lung metastases, liver lesions, and bulky nodal disease. However, its soft-tissue resolution in the pelvis is inferior to MRI for differentiating recurrence from scar tissue.

Modalities like `US pelvis transvaginal` are rated Usually Not Appropriate in this context because, while useful for initial evaluation of the endometrium, ultrasound cannot reliably distinguish post-treatment changes from recurrence and offers a limited field of view for assessing pelvic sidewalls and lymph nodes.

What’s Next After MRI? Downstream Workflow

The results of the imaging study will guide the subsequent clinical pathway, which almost always involves histologic confirmation before initiating further treatment.

If the study is positive for isolated local recurrence:
If MRI identifies a discrete, accessible lesion (e.g., at the vaginal cuff or a pelvic sidewall), the next step is a targeted biopsy to confirm malignancy. If confirmed, the patient may be a candidate for salvage therapy, such as focused radiation (e.g., brachytherapy or stereotactic body radiation therapy) or surgical resection (pelvic exenteration), depending on the location and prior treatments.

If the study is positive for nodal or distant metastatic disease:
When imaging reveals disease outside the pelvis (e.g., in para-aortic nodes, the peritoneum, or liver), the management strategy shifts. A biopsy of the most accessible metastatic site is performed to confirm recurrence. The patient is then typically considered to have systemic disease and is evaluated for systemic therapy, which may include chemotherapy, hormone therapy, or targeted/immunotherapy based on the tumor’s molecular profile.

If the study is negative or indeterminate:
A negative high-quality MRI in the face of strong clinical suspicion (e.g., rising CA-125 and a palpable finding) is challenging. The findings should be reviewed in a multidisciplinary tumor board. If suspicion remains high, an `FDG-PET/CT skull base to mid-thigh` may be considered to look for metabolically active disease missed by MRI. If a physical finding is present, an exam under anesthesia with directed biopsies may be warranted despite negative imaging. If both clinical suspicion and imaging are low, a transition to a surveillance plan, such as for an asymptomatic high-risk patient, may be appropriate, with close follow-up.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected recurrence requires careful attention to detail to avoid common errors.

  • Misinterpreting Post-Treatment Changes: Do not mistake expected post-radiation fibrosis or surgical scarring for recurrent disease. This is where MRI excels, but correlation with prior imaging and clinical history is essential.
  • Failing to Biopsy: Never initiate salvage therapy based on imaging findings alone. Histologic confirmation of recurrence is the standard of care, as imaging can be misleading and treatment carries significant morbidity.
  • Incomplete Staging: A pelvic-only study may miss distant disease. If MRI shows extensive pelvic recurrence or suspicious extra-pelvic findings, consider a whole-body staging study like PET/CT or a diagnostic CT of the chest, abdomen, and pelvis to fully assess disease burden.
  • Ignoring Renal Function: Both contrast-enhanced MRI and CT require adequate renal function. Always check a recent creatinine/eGFR before ordering studies with IV contrast.

If imaging findings are equivocal or discordant with the clinical picture, escalate the case to a multidisciplinary tumor board including gynecologic oncology, radiation oncology, and diagnostic radiology specialists.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a broader view of imaging across the entire patient journey, from initial diagnosis to surveillance, please consult the parent topic guide. For additional resources on selecting and understanding imaging studies, the following tools are available.

Frequently Asked Questions

Why is MRI preferred over CT for suspected pelvic recurrence of endometrial cancer?

MRI is generally preferred for suspected pelvic recurrence due to its superior soft-tissue contrast resolution. It is significantly better at differentiating recurrent tumor from benign post-treatment changes like radiation fibrosis and surgical scarring, which can look similar on CT. MRI sequences like diffusion-weighted imaging (DWI) are also highly sensitive for detecting cellular tumors.

If my patient has a contraindication to MRI (e.g., a non-compatible pacemaker), what is the next best test?

If MRI is contraindicated, `FDG-PET/CT skull base to mid-thigh` is an excellent alternative and is also rated Usually Appropriate by the ACR. It provides whole-body metabolic information and is highly sensitive for detecting recurrent and metastatic disease. A contrast-enhanced `CT chest abdomen pelvis` is another Usually Appropriate option that provides comprehensive anatomic information, though with less pelvic detail than MRI.

Is a non-contrast MRI useful in this scenario?

An `MRI pelvis without IV contrast` is rated as May be appropriate. While non-contrast sequences like T2-weighting and DWI are very helpful, the addition of gadolinium-based contrast improves the delineation of tumor margins, vascularity, and potential invasion into adjacent structures. A contrast-enhanced study is almost always preferred if the patient’s renal function allows.

Should I order a PET/CT for every patient with suspected recurrence?

Not necessarily. While PET/CT is rated Usually Appropriate, the choice between MRI and PET/CT depends on the specific clinical question. If suspicion is highest for a local, pelvic recurrence (e.g., a palpable vaginal cuff nodule), MRI is an excellent first choice for detailed anatomic characterization. If the clinical picture is more suggestive of widespread or distant disease, or if initial imaging is equivocal, PET/CT is often the preferred modality for its whole-body staging capability.

How does this imaging guidance change for an asymptomatic patient being followed after treatment?

This guidance is for symptomatic patients. The strategy for asymptomatic surveillance is different and depends on the initial stage and risk category of the cancer. For low- or intermediate-risk patients, routine imaging is often not recommended. For high-risk asymptomatic patients, surveillance imaging may be considered, but the protocol and frequency are distinct from the workup of a suspected recurrence. This represents a separate clinical scenario in the ACR Appropriateness Criteria.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026